Forbes
@forbes·2.1M subscribers·11.3K videos
Why 23andMe Is Betting Big On An Open Science Model
Posted
July 9, 2026
Views
578
Likes
14
Comments
3
Engagement
2.94%
July 9, 2026
578
14
3
2.94%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
32:17Now PlayingOn this episode oof Iconoclast, 23andMe CEO and Founder Anne Wojcicki sits down with Forbes to discuss 23andMe’s transformation from a public direct-to-consumer genetic testing company into a nonprofit research institute focused on preventative health. Wojcicki also discusses her personal family history with healthcare advocacy, the lessons she learned from navigating a complex public market corporate restructuring, and the company's citizen-powered open science platform.
Read the full story on Forbes
Subscribe to FORBES
Fuel your success with Forbes. Gain unlimited access to premium journalism, including breaking news, groundbreaking in-depth reported stories, daily digests and more. Plus, members get a front-row seat at members-only events with leading thinkers and doers, access to premium video that can help you get ahead, an ad-light experience, early access to select products including NFT drops and more:
Stay Connected
Forbes newsletters
Forbes on Facebook
Forbes Video on Twitter
Forbes Video on Instagram
More From Forbes
Forbes covers the intersection of entrepreneurship, wealth, technology, business and lifestyle with a focus on people and success.
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
